LYMPHOMA, B-CELL

This is an early-stage study testing the safety and initial effectiveness of a new drug combination called UB-VV111 plus rapamycin. It is for adults with certain advanced B-cell blood cancers (like lymphoma and leukemia) that have come back or stopped responding to other treatmen…

This study is testing a new, experimental CAR T-cell therapy called ronde-cel against currently approved CAR T-cell therapies for patients with aggressive large B-cell lymphoma that has returned or not responded to initial chemotherapy. The new therapy is designed to target two m…

This early study aims to find the safest, highest dose of a new drug when combined with standard lymphoma chemotherapy. It's for adults whose aggressive B-cell lymphoma has returned or hasn't responded to prior treatment. Researchers will carefully increase the dose for small gro…

This early-stage trial is testing a new drug called BTM-3566 in adults whose B-cell lymphoma has returned or hasn't responded to standard treatments. The main goals are to find a safe dose, check how the drug moves through the body, and see if it helps control the cancer. Partici…

This study is testing a new type of personalized immune cell therapy called prizlo-cel for adults with B-cell non-Hodgkin lymphoma that has returned or not responded to previous treatments, or for those with newly diagnosed high-risk disease. The therapy involves collecting a pat…

This study is testing if a special blood test can help doctors personalize treatment for a common type of lymphoma called DLBCL. The goal is to see if patients who show no signs of cancer in their blood halfway through standard chemotherapy can safely stop the chemo drugs early a…

This early-stage study is testing if adding one of two new drugs (iberdomide or CC-99282) to standard chemotherapy (R-CHOP) is safe and more effective for people newly diagnosed with aggressive B-cell lymphoma. Researchers will first find the safest dose, then expand the study to…

This study is testing if adding early palliative (comfort) care to standard cancer treatment improves well-being for patients with multiple myeloma or aggressive lymphoma. It will involve 144 patients, and some of their caregivers, who will be randomly assigned to receive either …

This study is testing a new training program called Hematolo-GIST, designed to help lymphoma doctors communicate more effectively with their patients. It involves 48 doctors and their patients with a specific type of aggressive lymphoma. The main goal is to see if the training is…

This study aims to understand why certain blood and lymph cancers sometimes run in families. Researchers are enrolling families where at least two blood relatives have been diagnosed with these cancers. The goal is to learn how genetics and environmental factors might work togeth…

This study aims to understand if CAR-T cell therapy, a powerful new cancer treatment, might affect heart function in the first few days after patients receive it. Researchers will follow 60 patients with blood cancers, performing heart ultrasounds before and shortly after their C…